A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)

Intervention/treatment:
PEGOZAFERMIN (BIO89-100)
Medical condition:
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Protocol code:
BIO89-100-132
Control number:
287944
Status:
Recruiting
Approved:
July 23, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06419374
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Reference Study ID Number: BIO89-100-132 ENLIGHTEN clinical trial / No attachments to email below.
Role
CONTACT
Phone:
888-662-6728 (U.S. Only)
Name
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Role
CONTACT
Sponsor
89BIO INC.

Locations

89bio Clinical Study Site
Vaughan, L4L 4Y7
WITHDRAWN
Name
89bio Clinical Study Site
Role
CONTACT

Alberta

89bio Clinical Study Site
Calgary, Alberta, T2N 4Z6
RECRUITING
Name
89bio Clinical Study Site
Role
CONTACT

British Columbia

89bio Clinical Study Site
Vancouver, British Columbia, V5Z 1M9
RECRUITING
Name
89bio Clinical Study Site
Role
CONTACT
89bio Clinical Study Site
Vancouver, British Columbia, V6Z2K5
RECRUITING
Name
89bio Clinical Study Site
Role
CONTACT

Manitoba

89bio Clinical Study Site
Winnipeg, Manitoba, R3E 3P4
RECRUITING
Name
89bio Clinical Study Site
Role
CONTACT

Ontario

89bio Clinical Study Site
London, Ontario, N6A5A5
RECRUITING
Name
89bio Clinical Study Site
Role
CONTACT
89bio Clinical Study Site
Ottawa, Ontario, K1H 8L6
RECRUITING
Name
89bio Clinical Study Site
Role
CONTACT
89bio Clinical Study Site
Toronto, Ontario, M6H3M1
RECRUITING
Name
89bio Clinical Study Site
Role
CONTACT
Did you find what you were looking for?

Contacts and resources